Abstract: A novel nanoparticle platform has been developed that induces and expands multiple populations of suppressive regulatory cells in vivo for the prevention and treatment of immune-mediated disorders. These include autoimmune diseases, graft-versus-host disease, and transplant rejection. The regulatory cells expanded include both CD4+ and CD8+ T cells and NK cells. The nanoparticles function as artificial antigen-presenting cells (aAPC) that target T cells and NK cells and provide them the essential stimulation and cytokines they require for regulatory cell generation, function, and expansion. This is achieved without the use of the toxic immunosuppressive and biological agents now in use.

Abstract: The present invention is directed to methods and compositions for expanding and stabilizing the phenotype of natural regulatory T cells. In particular, the present invention provides methods and compositions for treating natural regulatory T cells that renders the cells resistant to factors present in the inflammatory milieu and stabilizes the suppressive properties of the cells.

Abstract: The present invention is directed to methods and compositions for expanding and stabilizing the phenotype of natural regulatory T cells. In particular, the present invention provides methods and compositions for treating natural regulatory T cells that renders the cells resistant to factors present in the inflammatory milieu and stabilizes the suppressive properties of the cells.

Abstract: A method for inducing T cell tolerance in peripheral blood mononuclear cells (PBMCs) comprising adding a suppressive composition to said cells.

Abstract: The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.

Abstract: The field of the invention is generally related to methods used for the induction of T cells with suppressive activity. More specifically, the methods are used to generate professional regulatory T cells and cytokine-producing T cells with enhanced suppressive activity.

Abstract: The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation of T cells into suppressor cells, and agents that are histone deacetylase inhibitors. The invention also encompasses compositions of regulatory T cells generated by culturing non-regulatory T cells with a regulatory composition as well as the use of such regulatory T cells in the treatment of autoimmune diseases and aberrant immune responses.

Abstract: Methods and compositions for determining whether a T cell is a regulatory T cell and for determining whether a population of cells includes at least one regulatory T cell or a cell with the potential to become a regulatory T cell. The invention includes methods and compositions for detecting TGF-? on the surface of a cell. The invention also provides methods and compositions for evaluating the suppressive activity of a regulatory T cell based on the presence and/or the amount of membrane-bound TGF-?.

Abstract: A method for inducing T cell tolerance in peripheral blood mononuclear cells (PBMCs) comprising adding a suppressive composition to said cells.

Abstract: The invention relates to compositions and methods useful for preventing graft rejection in a recipient following organ transplantation.

Abstract: The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.

Abstract: The field of the invention is generally related to pharmaceutical agents useful in treating graft-versus-host disease (GVHD) in patents that have received allogenic bone marrow transplants.

Abstract: The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.

Abstract: The field of the invention is generally related to pharmaceutical agents useful in treating graft-versus-host disease (GVHD) in patients that have received allogenic bone marrow transplants.

Abstract: The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.

Abstract: The invention relates to compositions and methods useful for preventing graft rejection in a recipient following organ transplantation.

Abstract: The invention relates to compositions and methods useful for preventing graft rejection in a recipient following organ transplantation.

Abstract: The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.

Abstract: The field of the invention is generally related to methods used for the induction of T cells with suppressive activity. More specifically, the methods are used to generate professional regulatory T cells and cytokine-producing T cells with enhanced suppressive activity.

Abstract: The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.